The rise of theranostics: Part 4 -- Women's theranostics on the horizon
AuntMinnie
JULY 8, 2024
With CAM-H2, we engineered the protein to bind to a different epitope on HER2 to other approved therapies, so the option of combining CAM-H2 with other therapies is definitely an opportunity." In addition, the mean tissue dose did not reach the maximum tolerated dose for kidney, bone marrow, or liver.
105 
Let's personalize your content